|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
|---|---|
| Information provided by: | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
| ClinicalTrials.gov Identifier: | NCT00309699 |
Purpose
The purpose of this study is to evaluate the effectiveness and safety of flexible-doses paliperidone ER (3 to 12 mg as needed) compared with placebo over 3 weeks in patients with Bipolar I Disorder who are experiencing an acute manic or mixed episode. This study will also evaluate the effects of paliperidone ER on global functioning, and will compare the effectiveness of flexible doses of paliperidone ER to that of quetiapine over 12 weeks.
| Condition | Intervention | Phase |
|---|---|---|
|
Mood Disorders Bipolar Disorder |
Drug: Placebo Drug: Paliperidone ER Drug: Quetiapine |
Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study |
| Official Title: | Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Flexibly-Dosed Extended-Release Paliperidone Compared With Flexibly-Dosed Quetiapine and Placebo in the Treatment of Acute Manic and Mixed Episodes in Bipolar Disorder |
| Enrollment: | 493 |
| Study Start Date: | April 2006 |
| Study Completion Date: | November 2007 |
| Primary Completion Date: | November 2007 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| 001: Experimental |
Drug: Paliperidone ER
3 to 12 mg daily, flexibly dosed, for 12 weeks
|
| 002: Active Comparator |
Drug: Quetiapine
400 to 800 mg daily, initially titrated and flexibly dosed, for 12 weeks
|
| 003: Placebo Comparator |
Drug: Placebo
Daily for 3 weeks
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Study Director: | Johnson & Johnson Pharmaceutical Research and Development, L.L.C. Clinical Trial | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
More Information
| Responsible Party: | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. ( Compound Development Team Leader ) |
| Study ID Numbers: | CR010858, R076477BIM3002 |
| Study First Received: | March 31, 2006 |
| Last Updated: | October 3, 2008 |
| ClinicalTrials.gov Identifier: | NCT00309699 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
bipolar disorder mania Affective psychosis manic disorder mixed-state |
paliperidone paliperidone ER. manic-depressive psychosis manic state |
|
Disease Tranquilizing Agents Bipolar Disorder Physiological Effects of Drugs Psychotropic Drugs Central Nervous System Depressants 9-hydroxy-risperidone Antipsychotic Agents |
Pharmacologic Actions Affective Disorders, Psychotic Quetiapine Pathologic Processes Mental Disorders Therapeutic Uses Mood Disorders Central Nervous System Agents |